Business Wire

SHARJAH-GOVERNMENT

6.6.2022 17:43:08 CEST | Business Wire | Press release

Share
Sir Bu Nair Island, a Safe Haven for Rare Creatures

Around midnight on June 1, a hawksbill turtle landed on the Sir Bu Nair Island. It’s one of the many that began arriving three months ago to nest on the island, bringing the number of nests to more than 300 spread across 27 beaches. The hawksbill turtle lays between 90 to 110 eggs and quietly returns to the sea, leaving eggs to hatch in 50 to 70 days. Part of Sharjah, Sir Bu Nair is situated around 110 km north off the Emirate’s coast.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005699/en/

Declared a nature reserve by a government decree, the island is one of the most important breeding grounds for the endangered hawksbill turtle and features on the International Union for Conservation of Nature list.

The enchanting island, 13 sq km in size, is home to the sooty seagulls (Abu Sannin) and other terns who make thousands of nests in its red soil. Sharjah has strict laws in place to protect all living creatures on the island. Sir Bu Nair is rich in rare green sea turtles, deer, hedgehogs and reptiles. It has also recorded the discovery of the red coat fish.

Rich history

Sir Bu Nair Island has long been preserved in the region’s collective memory of historical events. The British established, during their presence in the region, the first railway in the Emirates, whose relics remain on one side of the beach under the sea.

The island is also known for the sweetness of its waters, which is also fabled to cure rare diseases.

Pottery vessels have been found on the island dating back to the Iron Age, i.e. about 3,500 years ago confirming the continuation of marine activity on the island during the past 35 centuries. There is a cemetery on the island that is known to contain the remains of a number of divers and miners, which represents an important stage in the history of the development of the people living on the banks of the Arabian Gulf.

Mars Island

The island is also known as Al-Jazirah Al-Hamra because of its red terrain and is often compared to the planet Mars. It’s rich in minerals, including sulfur and iron oxide. In the past, railways were used to transport minerals to ships for exporting abroad. Some mines survive to this day.

Known for its sandy beaches and its pristine waters, Sir Bu Nair and its surroundings are rich in coral and marine life, boasting more than 76 types of fish and 40 types of coral reefs.

Emirati poets have long described Sir Bu Nair as “the tear that fell in the waters of the Gulf.” The people of Sharjah have a strong affinity with the island thanks to their historical love of the sea and seafaring traditions. The island had been the seat of generations of pearldivers and fishermen.

International importance

The Sir Bu Nair reserve enjoys strategic global importance and is included in the International Convention on Wetlands because of its rich marine life. It’s included in the preliminary list of UNESCO World Heritage Sites, and an international agreement on the protection and management of sea turtles in the Indian Ocean and Southeast Asia.

HH Sheikh Sultan bin Ahmed Al Qasimi, Deputy Ruler of Sharjah, attended the 22nd Sir Bu Nair Festival, held on June 3-4 to highlight the island's environmental and touristic importance and consolidate the Emirati relationship with their environment and heritage.

Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye